KYS05001

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: KYS05001
• 英文别名: 4-(N-benzylacetamido)-3-phenyl-2-(piperidine-1-yl)-3,4-dihydroquinazoline；N-benzyl-2-(3-phenyl-2-(piperidin-1-yl)-3,4-dihydroquinazolin-4-yl)acetamide；N-benzyl-2-(3-phenyl-2-piperidin-1-yl-4H-quinazolin-4-yl)acetamide
• 化学式: C₂₈H₃₀N₄O
• 分子量: 438.572
• InChiKey: IROXHJVGJHVBSD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-nitrocinnamic acid 在 lithium hydroxide 、 硫酸 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 tin(ll) chloride 、 二溴三苯基膦 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 乙酸乙酯 、 苯 为溶剂， 反应 20.0h， 生成 KYS05001
  参考文献：
  名称：

  Synthesis and SAR studies of a novel series of T-type calcium channel blockers

  摘要：

  For the novel, potent, and selective T-type Ca2+ channel blockers, a series of sulfonamido-containing 3,4-dihydroquinazoline derivatives were prepared and evaluated for their blocking actions on T- and N-type Ca2+ channels. Among them, 9c (KYS05064, IC50 = 0.96 +/- 0.22 mu M) was found to be as potent as Mibefradil and also showed the highest selectivity for T-type Ca2+ channel with no effect on N-type Ca2+ channel. (c) 2006 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2006.01.005

文献信息

• 3,4-Dihydroquinazoline derivatives as T-type calcium channel blockers and method of preparing the same
  申请人：Korea Institute of Science and Technology

  公开号：EP1568695B1

  公开（公告）日：2016-03-09
• 3,4-Dihydroquinazoline derivatives as novel selective T-type Ca2+ channel blockers
  作者：Yong Sup Lee、Bum Hoon Lee、Seong Jun Park、Soon Bang Kang、Hyewhon Rhim、Jin-Yong Park、Jung-Ha Lee、Seong-Woo Jeong、Jae Yeol Lee

  DOI：10.1016/j.bmcl.2004.04.090

  日期：2004.7

  For LVA T-type Ca2+ channel blockers, 3,4-dihydroquinazoline derivatives as new scaffolds were prepared and evaluated for the inhibitory activity against two members of the recombinant T-type Ca2+ channel family. Among them, 8a (KYS05001, IC50 = 0-9 muM) was nearly equipotent with mibefradil (IC50 = 0.84 muM) and inhibited LVA T-type Ca2+ channel with greater efficacy than HVA Ca2+ channel. (C) 2004 Elsevier Ltd. All rights reserved.
• USES, COMPOSITIONS AND METHODS
  申请人：Fisahn Andre

  公开号：US20210038589A1

  公开（公告）日：2021-02-11

  The present invention relates generally to calcium channel inhibitors for use in treating and/or preventing an amyloid disease of the nervous system. The invention also relates to related pharmaceutical compositions, kits and screening methods.
• T-TYPE CALCIUM CHANNEL MODULATORS AND METHODS OF USE THEREOF
  申请人：Praxis Precision Medicines, inc.

  公开号：US20210128537A1

  公开（公告）日：2021-05-06

  Described herein are compounds useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy) and mood disorders. The present invention further comprises methods for modulating the function of a T-type calcium channel.
• US7271260B2
  申请人：——

  公开号：US7271260B2

  公开（公告）日：2007-09-18